Benefit of adding Cureety Techcare telemonitoring to usual care during injectable anticancer treatment: the OPTIMACURE multicentric French prospective randomized study.

BACKGROUND: In routine oncology care, assessing a patient’s suitability for injectable anticancer treatment involves several factors including blood tests and follow-up calls from hospital staff to review results and relevant factors. The OPTIMA program at the François Baclesse Comprehensive Cancer Center and the “Star” program at Foch Hospital in France have improved chemotherapy prescription accuracy and reduced wait times through structured calls and biological tests. However, these programs rely heavily on telephone calls, increasing staff workload. The Cureety digital telemonitoring platform could streamline this process by efficiently collecting and evaluating patient data, potentially reducing the number of outgoing calls. The OPTIMACURE study was implemented to assess whether integrating Cureety telemonitoring into usual care can decrease the workload on hospital staff compared to programs like OPTIMA. METHODS: The main aim of this prospective, randomized, multicenter, open-label study is to assess the effectiveness of adding Cureety telemonitoring to usual care to reduce the number of outgoing telephone calls from the center during the first two months after randomization. Patients initiating injectable anticancer treatment will be randomly allocated in a 2:1 ratio to either usual care with Cureety telemonitoring or usual care alone (OPTIMA or equivalent program). Randomization will be stratified by treatment type, Eastern Cooperative Oncology Group performance status, administration frequency, and participating center. A total of 192 patients will be recruited over four months, with patient participation planned for two months, making the study duration six months from the first enrollment. An interim analysis is planned once 96 patients reach the two-month visit. DISCUSSION: This study aims to validate telemonitoring as a more efficient alternative, potentially enhancing data collection and patient monitoring while reducing healthcare staff workload. The research aims to improve oncology care efficiency by integrating Cureety telemonitoring, reducing staff workload and improving patient care. It seeks to enhance the patient’s experience with timely data collection, leading to better quality of life, fewer emergency room visits, and potentially improved clinical outcomes. CLINICALTRIALS.GOV REGISTRATION NUMBER: NCT06371911, registered on April, 15, 2024. PROTOCOL VERSION: Version 2.1 dated from April, 16, 2024. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-025-13661-1.